This transformative research offers three essential clinical implications for managing ovarian cancer therapy resistance. First, genomic instability activates the STING pathway, which paradoxically shifts from tumor suppression to tumor promotion through myofibroblast transformation—suggesting that DNA-damaging therapies may inadvertently trigger resistance mechanisms. Second, the STING-WNT axis operates as a critical hub regulating the tumor microenvironment, where myofibroblast activation creates immunosuppression that shields cancer cells from both immune attack and PARP inhibitor exposure. Third, POSTN+ myofibroblasts emerge as actionable therapeutic targets; inhibiting their development or function could dismantle the protective microenvironment and restore treatment sensitivity. For clinical practitioners, these findings suggest that overcoming PARP inhibitor resistance requires combination strategies targeting not just cancer cells but also the supportive stromal compartment. Biomarkers reflecting STING-WNT axis activation may help identify patients at risk for treatment resistance before it develops. Read the full article on GMJ Newsroom.
Was this article helpful?
